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HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS 
INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS 
WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT 
US COMMUNITY ONCOLOGY CLINICS
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B2, Neary MP3, Duh MS1, Jolly P4
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OBJECTIVES: This study models the costs of mRCC treatment for selected targeted 
agents (AIs and mTORs) in 18 US community oncology clinics using medical resource 
utilization data collected from patient medical charts. METHODS: Data were 
abstracted for 297 non-trial mRCC patients ≥18 years, receiving sunitinib (n = 131), 
sorafenib (n = 119), bevacizumab (n = 19), or temsirolimus (n = 28) as ﬁrst-line tar-
geted agent. Per-patient-per-month (PPPM) costs (2009 USD) were estimated for 
targeted agents, intravenous administration, other drugs, procedures, hospitalizations, 
and treatment of adverse events (AEs; including drugs, procedures, hospitalizations, 
and ofﬁce visits for AE treatment). Drug costs were estimated using Average Wholesale 
Price, procedure costs were based on US private insurance reimbursement, hospitaliza-
tion costs were based on HCUP National Inpatient Sample discharge diagnosis charges 
and published average cost-to-charge ratio. RESULTS: Median treatment duration 
was 5.9 (sunitinib), 5.5 (sorafenib), 6.7 (bevacizumab), and 2.8 (temsirolimus) 
months. Total PPPM costs (mean ± SE) were $9,417.35 ± 670.78 (sunitinib), 
$7,992.48 ± 682.29 (sorafenib), $14,770.48 ± 1,393.25 (bevacizumab), and 
$11,493.39 ± 1,256.53 (temsirolimus). AI drug costs comprised 64% (sunitinib, 
sorafenib), 79% (bevacizumab), and 55% (temsirolimus) of total PPPM cost. AE 
treatment costs PPPM were $1,972.62 ± 560.86 (sunitinib, 21% of total PPPM costs), 
$1,302.58 ± 559.54 (sorafenib, 16%), $425.25 ± 265.69 (bevacizumab, 3%), and 
$1,810.85 ± 627.63 (temsirolimus, 16%). Given the median treatment durations, total 
costs over course of ﬁrst-line AI were estimated as $55,562 (sunitinib), $43,959 
(sorafenib), $98,962 (bevacizumab), and $32,181 (temsirolimus), including intrave-
nous administration costs of $2,497 (bevacizumab) and $2,111 (temsirolimus). CON-
CLUSIONS: Targeted agent drug cost was a major contributor to the total health care 
PPPM costs in patients with mRCC, followed by AE treatment costs. While AEs may 
be largely related to tolerability for sunitinib and sorafenib, AE treatment cost was as 
high as 21% and 16% of total cost. This study is limited by small sample sizes for 
bevacizumab and temsirolimus.
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HEALTH CARE COSTS ASSOCIATED WITH MULTIKINASE INHIBITORS 
(MKIS) FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA 
(MRCC) IN A CLINICAL PRACTICE SETTING IN ITALY
Paglino C1, Porta C1, Canipari C1, Antràs L2, Chen K2, Whittemore S2, Luka A2, 
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OBJECTIVES: A prior retrospective chart review study described treatment patterns 
and drug-related adverse events (AEs) for mRCC pts treated with sunitinib or 
sorafenib in a tertiary center in Italy (ECCO-ESMO, 2009). This study modeled the 
costs of these treatments and AEs. METHODS: Medical records were reviewed for 
non-trial pts with mRCC, ≥18 years old, treated with sunitinib (n = 85) or sorafenib 
(n = 60) after January 1, 2005. Data collected included patients’ health care resource 
utilization. Cost data for the Italian health care system were obtained from various 
sources including published literature and publicly available information from the 
Italian government. The components of the total per-patient-per-month (PPPM) costs 
(in 2008 Euro) included costs of MKI drugs, diagnostic and therapeutic procedures, 
hospitalizations, management of MKI-treatment-related adverse events (AEs), and 
prescription drugs for conditions other than mRCC. RESULTS: Median treatment 
duration was 6.6 months (sunitinib) and 5.8 months (sorafenib). Total costs PPPM 
were (mean ± SD) 33868.97 ± 710.49 (sunitinib) and 33448.01 ± 1,178.96 (sorafenib). 
MKI drug costs, equal to 33566.33 ± 481.36 (sunitinib) and 33110.85 ± 622.25 
(sorafenib), were the largest contributor to total PPPM costs, followed by AE treat-
ment costs of 3107.89 ± 405.42 (sunitinib) and 3222.16 ± 991.18 (sorafenib), and 
procedure costs of 375.48 ± 72.15 (sunitinib) and 379.94 (sorafenib). Given the 
median treatment durations, the total cost over the course of ﬁrst-line MKI treatment 
is estimated to be 325,535 for sunitinib and 319,998 for sorafenib, with the cost of 
AE treatment amounting to 3712 for sunitinib and 31,289 for sorafenib. CONCLU-
SIONS: This study used health care resource utilization data from a real clinic setting 
and costs from published literature to estimate costs associated with MKI treatment 
in patients with mRCC in Italy. MKI drug cost was the major contributor to total 
PPPM cost, followed by the cost associated with treatment of AEs. This retrospective 
study is limited by small sample sizes from a single center.
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RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF 
SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF 
PATIENTS WITH RENAL CELL CARCINOMA (RCC)
Moyneur E1, Dorff T2, Barghout V3, Meyers S3, Hu J2, Quinn D2
1StatLog Consulting Inc., L’Ange-Gardien, QC, Canada, 2USC Keck School of Medicine, Los 
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OBJECTIVES: An earlier analysis in ﬁrst-line treatment of RCC patients with similar 
baseline characteristics demonstrated signiﬁcantly greater costs with sunitinib than 
sorafenib. Evidence from case series supports the use of sorafenib or sunitinib sequen-
tial therapy for RCC disease control. Direct medical costs associated with each 
sequence were quantiﬁed. METHODS: Patients in MarketScan®, a U.S. health care 
claims database covering all U.S. census regions and >18 million lives annually from 
2002–2009, were retrospectively analyzed. Inclusion: ≥2 RCC claims (ICD9 189.0; 
198.0), continuous health care coverage, ≥1 switch (sorafenib to sunitinib; sunitinib 
to sorafenib), > 180 days’ coverage before switch date. Observation period: ﬁrst-line 
therapy ≤12 months before switch, ending ≤12 months after switch. Second-line 
therapy (switch) ended with next dispensing of sorafenib, sunitinib, bevacizumab, or 
temsirolimus; disenrollment; death; or study end (March 31, 2009). A person-time 
approach was used. Limitations include physician coding and lack of disease staging. 
RESULTS: At time of switch, no signiﬁcant differences in baseline characteristics 
existed between groups (sunitinib, n = 153; sorafenib, n = 119), except longer enrol-
ment in health plan in patients who received sorafenib ﬁrst (12.4 vs 8.8 months; 
P < 0.0001) and higher prevalence of anemia in patients who received sunitinib ﬁrst 
(52.9% vs 32.8%, P < 0.001). Univariate incremental total per member per month 
(PMPM) medical costs in those who received sunitinib ﬁrst were $1639 (P = 0.0003) 
more than those treated with sorafenib ﬁrst, largely due to signiﬁcantly higher outpa-
tient costs PMPM in those who received sunitinib ﬁrst ($1252; P < 0.0001). Overall, 
this represents an annual cost savings of $19,668 in RCC patients initially treated 
with sorafenib. CONCLUSIONS: In this retrospective US claims database analysis, 
we observed statistically signiﬁcantly lower costs in RCC patients initially treated with 
sorafenib, the difference mainly attributable to outpatient costs. Future cost analyses 
should be incorporated into prospective trials of RCC sequencing.
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LOWER HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH 
MANAGING NILOTINIB RELATED ADVERSE EVENTS IN CHRONIC 
MYELOID LEUKEMIA (CML) PATIENTS: EVIDENCE FROM A CLINICAL 
PRACTICE SETTING STUDY
Guerin A1, Bollu V2, Williams D2
1Analysis Group, Inc., Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA
OBJECTIVES: To compare the safety proﬁle of nilotinib, observed in a large study 
of CML patients in a clinical practice setting to the product information of nilotinib 
and dasatinib. METHODS: Adult patients with imatinib resistant or intolerant Ph+ 
CML in chronic phase (CP), accelerated phase (AP), or blast crisis (BC) were recruited 
in this phase IIIb, open label, multi-center study. Patients received nilotinib 400 mg 
BID and were not permitted to dose escalate. Follow-up treatment in managing the 
hematological and non-hematological adverse event (AE), were recorded. Health care 
resource utilization was estimated by constructing six-month marginal cost increase 
in patients who received follow-up care for the management of AE. Cost data were 
obtained from MedStat MarketScan database that contained over 5000 CML patients. 
RESULTS: A total of 207 patients (172 CP pts, 15 AP pts, and 20 BC pts) were 
enrolled in the study between June 2006–October 2008. The percentage of patients 
with grade 3/4 hematological AEs suspected of being study drug-related in CP and AP 
were thrombocytopenia (12%, 20%), neutropenia (9%, 27%), and anemia (1.2%, 
13%). The most frequent non-hematologic AEs (all grades) included rash, headache, 
nausea, and fatigue. The percentage of patients requiring additional therapy for the 
reported hematological AEs was less than 50% in most cases. Total medical costs 
associated with managing the AEs, estimated from MedStat cost data, for both hema-
tological and non-hematological AEs were $6314 over a 6-month period. Medical 
costs associated with managing hematological AEs made up the majority of these costs. 
The estimated costs from this study were signiﬁcantly lower compared to the estimated 
burden of the AEs in the product information for nilotinib or dasatinib ($9,730 and 
$12,372, respectively). CONCLUSIONS: Nilotinib related AE costs observed in this 
large clinical practice setting study compare favorably to the estimated costs from 
product information from nilotinib and dasatinib.
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COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF 
MEXICAN PATIENTS WITH NON-HODGKIN LYMPHOMA
Balderas-Peña LMA1, Contreras I2, Garduno-Espinoza J3, Mould-Quevedo JF4, Sat-Muñoz 
D1, Morgan-Villela G5, Mariscal-Ramírez I1, Lomelí-García M5, Hernández-Chavez GA1, 
Garcés-Ruiz OM1
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del 
Seguro Social, Delegación Cuauhtémoc. Distrito Federal, Mexico, 3Secretaría de Salud. 
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OBJECTIVES: To describe cost associated to the treatment of different stages of non 
Hodgkin lymphoma at the Social Security Mexican Institute (IMSS) from the health 
care payer’s perspective. METHODS: A cost study was made. Resource use and cost 
data were obtained from hospital (second and tertiary levels) records of 70 treated 
patients from July 2008 to February 2009 using the following inclusion criteria: 
patients older than 16 years with non-Hodgkin lymphoma histological diagnosis who 
accepted to be included in the protocol through informed consent. Although, patients 
excluded were those who showed a second malignant neoplasm or incomplete infor-
mation. We calculate mean,standard deviation (SD), median, 25 percentil and 75 
percentil for each clinical stage and statistical differences were estimated through 
ANOVA tests, p value <0.05 was considered signiﬁcant to show differences. RESULTS: 
The median total cost per patient was US $3150.19 (US $2482.67 to US $5300.16), 
the mean cost per chemotherapy was US $3595.96 (SD: US $693.27), mean cost to 
A34 Abstracts
radiotherapy was US $412.14 (SD: US $46.52). The mean cost per patient in each 
clinical stage to chemotherapy was I: US $3166.99 (SD: US $2258.67), II: US 
$3843.45 (SD: US $1381.09), III: US $5254.36 (SD: US $922.43), IV: US $2500.40 
(SD: US $1323.60) and the non classiﬁed: US $2565.25 (SD: US $1356.95) p 0.551. 
CONCLUSIONS: The results show that in México, in more expensive the treatment 
to patients with non-hodgkin lymphoma in clinical stage III.
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COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF 
MEXICAN BREAST CANCER PATIENTS
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OBJECTIVES: To describe costs associated to the treatment of different stages of 
breast cancer patients at the Social Security Mexican Institute (IMSS) from the health 
care payer’s perspective. METHODS: A cost study was elaborated. Resource use and 
cost data were obtained from hospital (second and tertiary levels) records of 313 of 
treated patients during July 2008 to February 2009 using the following inclusion 
criteria: women older than 16 years with breast cancer histological diagnosis who 
accepted to be included in the protocol through informed consent. Although, patients 
excluded were those who showed a second malignant neoplasm or incomplete infor-
mation. We calculate mean, median, 95% conﬁdence interval (95% CI) for each clini-
cal stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was found in US $6135.38 (95% CI, US $4216.19–US $9737.19); 
the median cost per chemotherapy cycle was US $615.48 (95% CI, US $425.98–US 
$1456.63); all chemotherapy treatment resulted in US $2702.03, (95% CI, US 
$1456.36–US $5503.49) and median costs per patient with radiotherapy resulted in 
US $1260.78 (95% CI, US $421.34–US $1260.78). The mean cost per patient in each 
clinical stage with chemotherapy was: I: US $1830.80 (95% CI, US $686.21–
$2975.39); II: US $5143.41 (95% CI, US $3570.19–$6716.62); III: US $4079.77 
(95% CI, US $2739.86–$5419.68); IV: US $4907.21 (95% CI, US $672.11–$9142.31) 
and the non classiﬁed patients: US $5250.66 (95% CI, US $3360.94–$7140.40); p = 
0.401. CONCLUSIONS: The results showed that at the IMSS, it is more expensive 
the treatment of breast cancer patients in clinical stage II; however, the less expensive 
treatments resulted for patients in clinical stage I. In addition, the treatment of non 
classiﬁed patients were the second most expensive according to our results.
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OBJECTIVES: To describe cost associated to the treatment of different stages of 
colorectal cancer at the Social Security Mexican Institute (IMSS) from the health care 
payer’s perspective. METHODS: A cost study was made. Resource use and cost data 
were obtained from hospital (second and tertiary levels) records of 115 treated patients 
from July 2008 to February 2009 using the following inclusion criteria: patients older 
than 16 years with colorectal cancer histological diagnosis who accepted to be 
included in the protocol through informed consent. Although, patients excluded were 
those who showed a second malignant neoplasm or incomplete information. We 
calculate mean,standard deviation (SD), median, 25 percentil and 75 percentil for each 
clinical stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was US $3,263.52 (US $2,111.29 to US $4,881.14), the mean cost 
per chemotherapy was US $484.16 (SD: US $113.95), mean cost to radiotherapy was 
US $402.40 (SD: US $57.20). The mean cost per patient in each clinical stage to 
chemotherapy was I: US $247.21 (SD: US $247.21), II: US $482.48 (SD: US $208.96), 
III: US $393.75 (SD: US $192.35), IV: US $986.17 (SD: US $631.59) and the non 
classiﬁed: US $386.88 (SD: US $105.18) p 0.521. CONCLUSIONS: The results show 
that in México, in more expensive the treatment to patients with colorectal cancer in 
clinical stage IV, the cheapest treatment was to patients in clinical stage I, the treatment 
to clinical stage II patients are the second most expensive according our results, prob-
ably associated to longer hospital stay.
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BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST 
CANCER: A COST-EFFECTIVENESS ANALYSIS
Fortune-Greeley A, Cornell P
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: Novel chemotherapies for metastatic breast cancer (MBC), such as 
bevacizumab, have the potential to extend progression-free survival but with a ﬁnan-
cial burden to health systems. We estimate the cost-effectiveness of bevacizumab in 
combination with paclitaxel as compared to paclitaxel alone from the perspective of 
the United States Medicare system. METHODS: We constructed a hybrid decision 
tree-Markov model to follow a cohort for ten years composed of 10,000 women ages 
65 and older with a diagnosis of MBC and no prior chemotherapy in the metastatic 
setting. Individuals in the model transitioned between three distinct states: stable 
disease, progressive disease, and death. Transition probabilities, cost and outcome 
data were obtained from clinical trials, published Medicare reimbursement rates, and 
the peer-reviewed literature. Incremental costs per quality-adjusted life year (QALY) 
were valued in 2009 US dollars. We discounted costs and survival at 3% per year. 
Deterministic and probabilistic sensitivity analyses tested the robustness of the model 
to variation in key parameters. RESULTS: In the base-case scenario, the bevacizumab 
plus paclitaxel arm had 22 additional days in quality-adjusted survival at an additional 
cost of $104,102 per patient, resulting in an incremental cost-effectiveness ratio 
(ICER) of $1.7 million/QALY. In the probabilistic sensitivity analysis, the ICER plane 
of 1,000 Monte Carlo simulation trials resulted in bevacizumab being more costly and 
more effective in 66.8% of samples and the dominated strategy in 34.1% of samples. 
In the deterministic sensitivity analysis, results were robust to changes in cost and 
utility parameters. Variation in time in progressive state and overall survival resulted 
in higher costs and slightly better outcomes; however, none of the sensitivity tests had 
positive ICERs below $50,000/QALY. CONCLUSIONS: Given the high cost in rela-
tion to its survival beneﬁts, it is unlikely that adding bevacizumab for MBC would be 
a cost-effective allocation of Medicare resources.
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THE POTENTIAL ECONOMIC BENEFITS PROVIDED BY COMBINING 
CISPLATIN WITH SRC INHIBITOR KX1–004 FOR CANCER REGIMENS
Henderson D1, Hayward A2, Purdy C3, Magar R4
1Univesity at Buffalo, Buffalo, NY, USA, 2AHRM Inc., Buffalo, NY, USA, 3AHRM Incorporated, 
Buffalo, NY, USA, 4AHRM Inc., Raleigh, NC, USA
OBJECTIVES: Cisplatin is a chemotherapeutic agent which is widely used and studied 
for multiple cancer types; however certain types of toxicity (ototoxicity, nephrotoxic-
ity and neurotoxicity) are associated with Cisplatin. Preclinical studies, performed on 
human testicular cancer cell lines, have indicated that combining Cisplatin with a Src 
Inhibitor (KX1–004) may signiﬁcantly mitigate toxicity related damage. To utilize the 
results from preclinical studies examining the beneﬁt of combining Cisplatin with 
KX1–004 in conjunction with cost of illness estimates from the literature to estimate 
the potential economic beneﬁts which could result from KX1–004 utilization. 
METHODS: Data from preclinical studies examining the toxicity limiting efﬁcacy of 
KX1–004 was combined with clinical and economic data from the literature with 
respect to the estimated cost of health care resources related to the speciﬁed toxic 
effects. This efﬁcacy and costing information was combined within a decision tree 
model to estimate the potential cost savings. RESULTS: The preclinical data indicates 
that KX1–004 may have a protective effect with respect to the neurotoxic, nephrotoxic 
(22% less damage) and ototoxic (82% less damage) effects. The Src inhibitor, when 
used alone and in conjunction with Cisplatin, exhibited the potential to slow tumor 
growth and maintain overall body mass. The economic modeling resulted in a poten-
tial per patient cost savings of $1633 resulting from mitigation of the ototoxic and 
nephrotoxic effects. CONCLUSIONS: Recent research has indicated that Cisplatin 
should be considered as a component of the standard therapy regimen for certain 
cancer types; however toxicity remains a signiﬁcant concern. When Cisplatin is used 
within a regimen which includes KX1–004, the beneﬁts may include decreased damage 
due to toxicity and an improvement in quality of life. The Src inhibitor may also 
provide a survival beneﬁt by enabling patients to remain on a regimen which includes 
Cisplatin.
PCN60
COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED 
COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE 
TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS
Hsiao FY1, Mullins CD1, Onukwugha E, Pandya NB2, Seal B3, Hanna N2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland 
Medical Center, Baltimore, MD, USA, 3Sanoﬁ-Aventis Pharmaceuticals, Bridgewater, NJ, USA
OBJECTIVES: Clinical trials have shown a statistically signiﬁcant disease-free survival 
beneﬁt of oxaliplatin or irinotecan based combination therapy for stage IV colon 
cancer. However, less is known regarding the comparative effectiveness and cost-
effectiveness of these agents among elderly patients. Whether the additional beneﬁt of 
these two agents is worth the additional cost for elderly Medicare recipients is particu-
larly policy relevant. METHODS: A cost-effectiveness analysis of oxaliplatin or iri-
notecan based combination therapy versus 5-ﬂuorouracil/leucovorin (5FU/LV) in 
patients aged 66 or older with stage IV colon cancer was performed from a US Medi-
care health care payer perspective. Survival and direct medical costs were estimated 
using patient-level data from the 1997–2007 surveillance, epidemiology, and 
end results (SEER)-Medicare datasets for patients diagnosed through 2005. Incremen-
tal cost-effectiveness ratio (ICER) was calculated and expressed as cost per life-year 
